Attend these presentations during the 64th ASH annual meeting to see how NGS is advancing hemato-oncology studies

Umbrella trial in myeloid malignancies: the MyeloMATCH National Clinical Trials Network precision medicine initiative
- **Number:** 4080
- **Presenter:** Richard Little
- **Session:** 616. Acute myeloid leukemias: investigational therapies, excluding transplantation and cellular immunotherapies: Poster III
- **Time and location:** Monday, December 12, 2022: 6:00–8:00 p.m., Hall D (Ernest N. Morial Convention Center)

Clinical features and mutational landscape of patients referred for suspected essential thrombocytosis: a descriptive study using a real-world database
- **Number:** 3546
- **Presenter:** Ala Almanaseer
- **Session:** 903. Health services and quality—myeloid malignancies: Poster II
- **Time and location:** Sunday, December 11, 2022: 6:00–8:00 p.m., Hall D (Ernest N. Morial Convention Center)

Bone marrow microenvironment changes in myelodysplastic neoplasms and their relationship with clonal hematopoiesis and disease progression
- **Number:** 1751
- **Presenter:** Antonieta Molero Yordi
- **Session:** 636. Myelodysplastic syndromes—basic and translational: Poster I
- **Time and location:** Saturday, December 10, 2022: 5:30–7:30 p.m., Hall D (Ernest N. Morial Convention Center)

Impact of higher calreticulin gene mutation variant allele frequency in patients with myelofibrosis
- **Number:** 1720
- **Presenter:** Chiara Maccari
- **Session:** 634. Myeloproliferative syndromes: clinical and epidemiological: Poster I
- **Time and location:** Saturday, December 10, 2022: 5:30–7:30 p.m., Hall D (Ernest N. Morial Convention Center)

Learn more at oncomine.com/ash2022